Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-07-28 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
内部审计制度
Governance Information Classification · 95% confidence The document is titled as an internal audit system of a company, detailing the internal audit policies, responsibilities, organizational structure, and procedures. It references internal control evaluation, audit committee roles, and compliance with laws and regulations. There is no indication that this is an actual audit report with audit results or financial statements, nor is it a certification or announcement of a report. Instead, it is a governance document outlining internal audit rules and procedures. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-07-28 Chinese
关于开立募集资金专项账户并签订募集资金专户存储三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the opening of a special account for raised funds and the signing of a tripartite supervision agreement related to the management and use of those funds. It details the regulatory approvals, the parties involved, and the terms of the agreement. There are no financial statements, earnings data, or detailed financial analysis present. The document is relatively short (2937 characters) and serves as a formal notification about fundraising account management rather than a financial report or detailed investor presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2025-07-18 Chinese
关于2024年限制性股票激励计划第一个归属期归属结果暨股份上市的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of the first vesting period of a 2024 restricted stock incentive plan and the listing of these shares. It details the decision-making process, the number of shares vested, the listing date, shareholding changes, and the impact on recent financial reports. It includes information about share issuance, stock registration, and compliance with regulatory requirements. The document is not a full financial report but an official announcement about share issuance and stock listing related to an equity incentive plan. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is 4121 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report.
2025-07-10 Chinese
股东权益变动触及1%刻度及减持计划完成暨减持股份结果公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement about a controlling shareholder's shareholding changes and completion of a share reduction plan. It includes specific data on share quantities, percentages, dates, and the nature of the shareholding changes. The document is not a financial report, earnings release, or management discussion. It is not a proxy solicitation or AGM material. The focus is on the change in major shareholding and the completion of a reduction plan, which fits the definition of a Major Shareholding Notification (MRQ). The document length is over 6000 characters, indicating it is a full announcement rather than a brief note or a report publication announcement. Therefore, the classification is MRQ with high confidence.
2025-07-09 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by 科兴生物制药股份有限公司. It details the stock price movement over three trading days, confirms no undisclosed material information, and reminds investors of risks. It does not contain financial statements, earnings data, or detailed management discussion. It is a regulatory announcement about stock price behavior and company disclosures related to that event. The document length is short (2369 characters) and it is clearly an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-03 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress of its share repurchase program, detailing the number of shares repurchased, the price range, total amount spent, and regulatory compliance. It references previous announcements about the repurchase plan and price adjustments but primarily focuses on the update of the repurchase progress. The document length is 1737 characters, which is relatively short and typical for a progress announcement rather than a full financial report. The content is about the company's buying back its own shares, which fits the category of Transaction in Own Shares (POS).
2025-07-02 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.